Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)
Terminated
Genentech, Inc.
Phase 4
2008-01-01
The purpose of this study is to determine if calcipotriene/bethamethasone can safely and
effectively manage the occurence of LMB (mild localized breakthrough) in patients recieving
efalizumab (Raptiva) for moderate to severe plaque psoriasis.
It is hypothesized that calcipotriene/betamethasone (Taclonex) could be used to manage LMB
and thus allow patients to continue efalizumab without interruption.
Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)
Terminated
Derm Research, PLLC
Phase 4
2008-01-01
The purpose of this study is to determine if calcipotriene/bethamethasone can safely and
effectively manage the occurence of LMB (mild localized breakthrough) in patients recieving
efalizumab (Raptiva) for moderate to severe plaque psoriasis.
It is hypothesized that calcipotriene/betamethasone (Taclonex) could be used to manage LMB
and thus allow patients to continue efalizumab without interruption.
Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis
Completed
Wake Forest University
Phase 4
2007-08-01
The purpose of this research study is to better understand how this study drug works when
people use it to treat atopic dermatitis. Desonate has been approved by the US Food and Drug
Administration (FDA) for atopic dermatitis.
Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis
Completed
Promius Pharma, LLC
Phase 4
2009-03-01
This study compares the effectiveness of two topical creams for atopic dermatitis in
pediatric subjects. Subjects will be randomly assigned to use one of the two creams twice
daily for 6 weeks or until clear.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
